Form 4: MAXCYTE Director Rekha Hemrajani Boosts Stake with Significant Equity Grant

MAXCYTE, Inc. Director Rekha Hemrajani has acquired 29,210 restricted stock units and 50,790 stock options as part of an annual equity grant, aligning her interests with shareholders.

Summary

• Rekha Hemrajani, a Director of MAXCYTE, Inc. (MXCT), acquired 29,210 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 18, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• These RSUs were granted at a price of $0 and are part of an annual grant under the Issuer's Equity Grant Policy for non-employee directors.
• The 29,210 RSUs are scheduled to vest on June 18, 2026, contingent upon Ms. Hemrajani's continuous service as a director.
• Following this transaction, Ms. Hemrajani's direct beneficial ownership of Common Stock (including RSUs) stands at 50,577 shares.
• Additionally, Ms. Hemrajani acquired 50,790 stock options on June 18, 2025, with an exercise price of $2.11 per share.
• These stock options were also granted at a price of $0 and are part of the annual grant policy for non-employee directors.
• The stock options are exercisable from June 18, 2025, and have an expiration date of June 17, 2035.
• Following this transaction, Ms. Hemrajani's direct beneficial ownership of stock options stands at 50,790.
• The filing was signed by David Sandoval, Attorney-in-Fact, on June 23, 2025, under a Power of Attorney granted by Rekha Hemrajani on February 19, 2025.

Sentiment

Score: 6

Explanation: The document reports a routine, expected equity grant to a director, which is generally a neutral to slightly positive event as it aligns director interests with shareholders. There are no negative financial implications or unexpected events reported.

Positives

• The acquisition of restricted stock units and stock options by a director aligns their financial interests with those of the company's shareholders, promoting long-term value creation.
• The equity grants are part of a pre-established 'Equity Grant Policy for non-employee directors,' indicating a structured and transparent compensation approach.

Risks

• The vesting of the restricted stock units is subject to the reporting person's continuous service as of the vesting date, meaning the shares could be forfeited if service is terminated before June 18, 2026.

Future Outlook

The document indicates a future vesting event for the Restricted Stock Units on June 18, 2026, contingent on the director's continued service.

Industry Context

This Form 4 filing reflects a routine equity compensation event for a non-employee director, a common practice across various industries, including biotechnology and life sciences, to attract and retain qualified board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to non-employee directors is a standard practice in publicly traded companies, particularly in the biotechnology sector, to incentivize long-term commitment and performance.
• The vesting schedule for RSUs (one year from grant date) is typical for annual director grants, ensuring continued service.
• The exercise price of the stock options ($2.11) is likely the closing price of the stock on the grant date, which is a common and compliant method for option grants.

Corporate Governance

Related Party Transactions

• The acquisition of 29,210 Restricted Stock Units and 50,790 Stock Options by Rekha Hemrajani, a director of MAXCYTE, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's long-term interests with those of the shareholders, potentially fostering decisions that enhance shareholder value. It also represents a form of non-cash compensation that conserves company cash.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The grant is consistent with the company's established compensation policies for non-employee directors, reflecting standard corporate governance practices.

Next Steps

• The 29,210 Restricted Stock Units are scheduled to vest on June 18, 2026, subject to the director's continuous service.

Key Dates

Keywords

MAXCYTE, MXCT, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership, Corporate Governance